Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Oncotarget
|
October 27, 2015
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
Dominik Bogen, Jun S Wei, David O Azorsa, et al.
Nature Communications
|
February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Sabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
Cancer Discovery
|
August 7, 2025
Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Giulia Montuori, Fengyu Tu, Di Qin, et al.
Nature Communications
|
May 3, 2024
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations
Ingrid M Saldana-Guerrero, Luis F Montano-Gutierrez, Katy Boswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
Cancer Cell
|
December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Sabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
The Journal of Molecular Diagnostics : JMD
|
October 19, 2025
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
Alexandra Saint-Charles, Julien Masliah-Planchon, Elnaz Saberi-Ansari, et al.
The Journal of Clinical Investigation
|
February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma
Lisa Werr, Jana Boland, Josephine Petersen, et al.
JCO Precision Oncology
|
July 1, 2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study
Hannah E Hartley, Fang Chyi Fong, Alem S Gabriel, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Oncotarget
|
October 27, 2015
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
Dominik Bogen, Jun S Wei, David O Azorsa, et al.
Nature Communications
|
February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Sabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
Cancer Discovery
|
August 7, 2025
Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Giulia Montuori, Fengyu Tu, Di Qin, et al.
Nature Communications
|
May 3, 2024
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations
Ingrid M Saldana-Guerrero, Luis F Montano-Gutierrez, Katy Boswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
Cancer Cell
|
December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Sabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
The Journal of Molecular Diagnostics : JMD
|
October 19, 2025
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
Alexandra Saint-Charles, Julien Masliah-Planchon, Elnaz Saberi-Ansari, et al.
The Journal of Clinical Investigation
|
February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma
Lisa Werr, Jana Boland, Josephine Petersen, et al.
JCO Precision Oncology
|
July 1, 2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study
Hannah E Hartley, Fang Chyi Fong, Alem S Gabriel, et al.
Page
of 5